Our strategy relies on R&D investments and further growth of our own full-cycle production. We foresee implementation of our plans through three strategic priorities:
- Securing our positions in the synthesis of active pharmaceutical substances
- Leadership in the innovative drug creation and expanding the scope of our existing portfolio
- Diversifying the portfolio with new therapeutic drug groups and formulations